Valneva

Reliance On Limited Vaccines Will Invite Setbacks Yet Spur Recovery

AnalystLowTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

02 Sep 25

AnalystLowTarget's Fair Value

€3.75

4.5% undervalued

02 Sep

€3.58

15.9%

-4.6%

15.9%

-4.6%

Edit anytime before Sep 2 10:12 PM. Then post Updates to your followers.

Author's Valuation

€3.8

4.5% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

€3.8

4.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

19.26%

Biotech revenue growth rate

7.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.41%

Calculation

€26.50m

Earnings '28

47.02x

PE Ratio '28

€1.25b

Market Cap '28

€1.25b

Market Cap '28

276.35m

No. shares '28

€4.51

Share Price '28

€4.51 Share Price '28

Discounted to 2025 @ 6.34% p.a.

€3.75

Fair Value '25